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Ultrasound-guided percutaneous delivery of
tissue-engineered endothelial cells to the
adventitia of stented arteries controls the response
to vascular injury in a porcine model
Helen M. Nugent, PhD,a,b Yin-Shan Ng, PhD,a Desmond White, BS,a Adam Groothius, PhD,b,c
Glenn Kanner, BS,a and Elazer R. Edelman, MD, PhD,b,d Cambridge, Lexington, and Boston, Mass
Objective: High restenosis rates are a limitation of peripheral vascular interventions. Previous studies have shown that
surgical implantation of a tissue-engineered endothelium onto the adventitia surface of injured vessels regulates vascular
repair. In the present study, we developed a particulate formulation of tissue-engineered endothelium and a method to
deliver the formulation perivascular to injured blood vessels using a percutaneous, minimally invasive technique.
Methods: Stainless steel stents were implanted in 18 balloon-injured femoral arteries of nine domestic swine, followed by
ultrasound-guided percutaneous perivascular injection of gelatin particles containing cultured allogeneic porcine aortic
endothelial cells (PAE). Controls received injections of empty particles (matrix) or no perivascular injection (sham) after
stent deployment. Animals were sacrificed after 90 days.
Results: Angiographic analysis revealed a significantly greater lumen diameter in the stented segments of arteries treated
with PAE/matrix (4.72  0.12 mm) compared with matrix (4.01  0.20 mm) or sham (4.03  0.16 mm) controls
(P< .05). Similarly, histologic analysis revealed that PAE/matrix-treated arteries had the greatest lumen area (20.4 0.7
mm2; P< .05) compared with controls (16.1 0.9 mm2 and 17.1 1.0 mm2 for sham andmatrix controls, respectively)
and the smallest intimal area (3.3  0.4 mm2; P < .05) compared with controls (6.2  0.5 mm2 and 4.4  0.5 mm2 for
sham and matrix controls, respectively). Overall, PAE-treated arteries had a 33% to 50% decrease in percent occlusion
(P < .05) compared with controls. Histopathological analysis revealed fewer leukocytes present in the intima in the
PAE/matrix group compared with control groups, suggesting that the biological effects were in part due to inhibition of
the inflammatory phase of the vascular response to injury.
Conclusions: Minimally invasive, perivascular delivery of PAE/matrix to stented arteries was performed safely using
ultrasound-guided percutaneous injections and significantly decreased stenosis. Application at the time of or subsequent
to peripheral interventions may decrease clinical restenosis rates. ( J Vasc Surg 2012;56:1078-88.)
Clinical Relevance: Endovascular interventions performed in the peripheral circulation are limited by restenosis.
Thrombosis, inflammation, smooth muscle cell proliferation, and negative remodeling result in significant obstruction to
the blood vessel lumen. While some trials have shown the beneficial effects of drug-eluting stents, data from large,
randomized controlled clinical trials of peripheral arterial disease are lacking. In a large animal model of peripheral arterial
stenting, we demonstrated that perivascular, ultrasound-guided injections of matrix-embedded endothelial cells signif-
icantly increased lumen diameter and decreased stenosis at 90 days. Development of techniques to deliver viable,
functional cells is essential to realize the potential therapeutic impact of cell transplantation and expands the opportunity
for the clinical application of cell-based therapy subsequent to endovascular interventions for peripheral arterial disease.
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cularization of peripheral vessels due to atherosclerosis is
the high rates of restenosis. Despite initial technical success,
restenosis after angioplasty or stent implantation occurs in
approximately 50% of the treated vessels, such as the super-
ficial femoral artery (SFA), within 6 to 12 months.1-3
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nd 61% after bare metal stent implantation. While the use
f drug-eluting stents in the coronary circulation has de-
reased restenosis rates, a benefit of stenting and drug
lution in peripheral arteries has yet to be clearly demon-
trated.4,5 A study of sirolimus-coated stents in the SFA
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Volume 56, Number 4 Nugent et al 1079reported that the drug-eluting stents were not superior to
bare metal stents.6 Studies have demonstrated a benefit of
paclitaxel-coated angioplasty balloons in the femoropopli-
teal artery7,8 and of paclitaxel-coated stents in the SFA;
however, long-term data in large, randomized clinical trials
of peripheral arterial disease are lacking.
Vascular restenosis is a complex response to injury that
occurs after all arterial interventions. The combined effects
of local injury, thrombosis, inflammation and leukocyte
infiltration, spasm, smooth muscle cell (SMC) prolifera-
tion, and vessel remodeling induce a hyperplastic response
that encroaches on the blood vessel lumen.9,10 In recent
years, the adventitia has emerged as a key component of the
vascular response to injury.11 Endothelial cells (ECs), the
major regulatory cells of the blood vessel, reside not only at
the lumen interface but also within the adventitia and
throughout the vessel as vasa vasorum. Experimental evi-
dence suggests an association between vasa vasorum and
neointimal formation after injury.12 Therefore, it was pos-
tulated that supplementing the adventitial endothelium
may provide control over the response to vascular injury.
Indeed, open surgical placement of perivascular tissue-
engineered ECs has been shown to inhibit intimal thicken-
ing, stenosis, and negative remodeling in experimental
models of vascular injury.13-16 While open field surgery is
amenable to direct adventitial placement, the question
arises as to whether tissue-engineered ECs could be applied
by a minimally invasive technique and retain efficacy. De-
velopment of techniques to deliver viable, functional cells is
essential to capitalize on the potential therapeutic impact
and clinical utility of cell transplantation.17 In the present
study, we investigated the vascular response to stent-in-
duced injury in porcine femoral arteries treated with gelatin
particles containing allogeneic porcine aortic endothelial
cells (PAE) injected adjacent to the affected vessel, using an
ultrasound-guided visualization technique.
METHODS
Endothelial cell culture on Gelfoam particles. PAE
were isolated from the aorta of healthy pigs by collagenase
digestion and cultured on gelatin particles (Gelfoam Pow-
der; Pfizer, New York, NY) as previously described.18,19
Growth on Gelfoam was evaluated by periodic evaluation
of cell number after enzymatic digestion.16 Cell viability
was assessed by trypan blue exclusion, and EC was allowed
to reach a growth plateau prior to implantation. EC integ-
rity was assessed by immunocytochemistry using a mouse
antiporcine CD31 antibody (MCA1746G; AB-D Serotec,
Raleigh, NC) to stain for platelet endothelial cell adhesion
molecule (PECAM). Nonspecific binding sites were
blocked with normal donkey serum. Alexa Fluor 488-
conjugated donkey antimouse secondary antibody (1:300;
Invitrogen, Grand Island, NY) was added, and cells were
counterstained with 4’,6-diamidino-2-phenylindole (DAPI).
Control particles (matrix) were incubated for up to 2 weeks in
medium prior to implantation.
Biochemical and in vitro functional activity.
Functional testing was performed on conditioned media trom in vitro cohorts as previously described.13,19 The
roduction of heparan sulfate (HS), transforming growth
actor-1 (TGF-1), nitric oxide (NO), and tissue inhibitor
f metalloproteinase-2 (TIMP-2) were used as markers of
C function. HS levels in conditioned media were deter-
ined using a dimethyl methylene blue binding assay.
GF-1, TIMP-2, and NO concentrations were deter-
ined by enzyme-linked immunosorbent assay (R&D Sys-
ems, Minneapolis, Minn). The ability of PAE on gelatin
articles (PAE/matrix) to inhibit proliferation was deter-
ined using conditioned media in an SMC growth stimu-
ation assay. Porcine aortic SMC were seeded in SMC
rowth medium (SmGM-2, Lonza BioScience [Walkers-
ille, Md], contains 5% fetal bovine serum [FBS], fibroblast
rowth factor, and epidermal growth factor), allowed to
ttach for 24 hours, and growth arrested for 48 to 72 hours.
onditioned and control media was diluted 1:1 with 2
mGM-2 and added to the wells. Cell number was deter-
ined after 3 days by colorimetric analysis (CellTiter 96
roliferation Assay; Promega, Madison, Wisc). Growth
actor stimulation (GFS) was determined by dividing the
bsorbance (ABS) of conditioned or control media wells by
he ABS for 5% FBS wells. The effect of conditioned media
n SMC growth factor stimulation was then determined by
he following equation:
(SmGM 2 GFS) (conditioned or control GFS)
(SmGM 2 GFS) 1
 100
The ability of PAE/matrix-conditioned media to sup-
ress markers of inflammation and thrombosis was deter-
ined using real-time polymerase chain reaction (RT-
CR). Briefly, human aortic EC (HAE) were grown to
onfluence and serum-starved in 0.5% FBS for 24 hours.
ells were treated with endothelial basal medium supple-
ented with 0.5% FBS (control media) alone or supple-
ented with 1 g/mL of platelet factor-4 (PF-4; Pepro-
ech, Rocky Hill, NJ) or with media conditioned by PAE/
atrix supplemented with 1 g/mL of PF-4 for 3.5 hours.
F-4 is a proatherogenic platelet molecule that has been
hown to increase E-selectin RNA as well as other inflam-
atory and thrombotic markers and was added to EC
ultures to simulate an injured state.20 RNA samples were
arvested from each individual well using the RNeasy Mini
pin column kit (Qiagen, Valencia, Calif) according to the
anufacturer’s protocol. The concentration of the repre-
entative RNA samples was determined using the Experion
apillary electrophoresis apparatus with the Experion RNA
tdSens analysis kit (Bio-Rad, Hercules, Calif). The result-
ng total RNA samples from each treatment group were
sed for RT-PCR analysis to determine the expression
evels of various inflammatory and thrombotic genes (Table
). The “2-Ct” calculation for relative gene expression
omparison method was used for PCR data analysis: the
elative expression level of each gene (Ctgene) was first
ormalized to the house-keeping marker hypoxanthine
ibosyltransferase (HPRT) to generate the Ct value
Ct – Ct ), which was then further normalized togene HPRT
he respective treatment control (control media with PF-4)
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October 20121080 Nugent et alto generate the Ct. The 2Ct value of each gene
representing the relative expression level was calculated and
plotted for data presentation.
In vivo biologic activity of transplanted endothelial
cells. The ability of the PAE/matrix to control vascular
repair when injected adjacent to stented porcine femoral
arteries was assessed. This study conformed to the guide-
lines specified in the National Institutes of Health “Guide
for Care andUse of Laboratory Animals” and was approved
by the Institutional Animal Care and Use Committee of
Concord BioMedical Sciences and Emerging Technologies
(Lexington,Mass).Male domestic pigs, 43.1 kg 0.9 kg at
implant, were obtained from Animal Biotech, Inc (Dan-
boro, Pa). Anesthesia was induced and animals monitored
throughout the procedure as previously described.18 To
prevent or reduce the occurrence of thrombotic events,
animals were treated on day 1 with aspirin (650 mg per os
[PO]) and clopidogrel (300 mg, PO). The animals were
then treated with aspirin (81 mg, PO) and clopidogrel (75
mg, PO) daily thereafter.
A total of nine pigs were implanted with stents in the
right and left femoral arteries (total stented arteries, 18).
This study was conducted in compliance with the Food and
Drug Administration Good Laboratory Practice Regula-
tions. Briefly, right carotid arterial access was obtained, and a
5.0-mm-diameter angioplasty balloon (AbbottVascular,Red-
wood City, Calif) was advanced to the left and right femoral
arteries under fluoroscopic guidance (GE 9800 C-arm fluo-
roscope [GE Healthcare, Wauwatoga, Wisc], resolution 15
frames per second). The right and left arteries were injured by
30-second balloon inflations at 10 atmospheres pressure
(three inflations per side, in overlapping segments) to ensure
adequate removal/injury of endogenous luminal endothe-
lium. Biliary stents (5.5 mm  18 mm, Herculink; Abbot
Vascular) were introduced into the left and right femoral
arteries. Angiography was performed, and the stents were
expanded with the 5.0-mm-diameter angioplasty balloon at
10 to 12 atmospheres pressure.Heparin (50-200U/kg intra-
venously) was administered to prolong activated clotting time
(ACT) to a target range of  275 seconds during stent
deployment. After final angiography to assess vessel patency,
Table I. Primer sets for real-time polymerase chain reactio
Genes Functional pa
Vascular adhesion molecule-1 Inflammation
Intercellular adhesion molecule-1 Inflammation
Tissue factor Coagulation
Thrombosis
E-selectin Inflammation
Interleukin-8 Inflammation
Smooth muscle ce
Hypoxanthine ribosyltransferase Metabolism
House-keepingthe femoral arteries were treated with minimally invasive in- fiections of 70 mg/3.0 mL media of control matrix (n 6
rteries, two arteries per animal), PAE/matrix (n 6 arteries,
wo arteries per animal), or no perivascular injection (sham,
 6 arteries, two arteries per animal) adjacent to the perivas-
ular tissue of the stented artery. Contralateral arteries re-
eived the same treatment to allow for blood collection at 4, 8,
nd 12weeks to assess differences in clinical pathology, hema-
ological, serum chemistry, and coagulation parameters be-
ween treatment groups. Animals were euthanized at 90 days,
nd the femoral arteries plus stent were processed for histo-
ogic evaluation. For each artery, angiography was performed
rior to injury, immediately after stent deployment, and on
ay 90.Quantitative angiographywas performed on recorded
mages using Centricity Cardiology CA1000 Cardiac Review
.0 (SpaII) QCA software in a blinded fashion (GE Health-
are). Measurements were also made of the reference un-
tented vessel and minimum lumen diameter (MLD) at 90
ays.
To verify the location of the injected material, a sepa-
ate non-Good Laboratory Practice study was performed in
even pigs. Stented and nonstented arteries were injected
ith either control particles stained with methyl blue or
articles seeded with PAE. All pigs were sacrificed within 1
ay, and tissue was isolated to determine the location of the
njected material.
Ultrasound-guided percutaneous injections. Control
atrix or PAE/matrix was delivered to the perivascular site
f stented femoral arteries percutaneously using a syringe
nd hypodermic needle. Delivery of the material was visu-
lized by ultrasound-guided needle placement techniques
sing echogenic needles (18G Chiba biopsy needle; Cook
edical, Bloomington, Ind). A portable ultrasound system
model t-3000; Terason, Inc, Burlington, Mass) was used
o visualize the targeted perivascular tissue, the needle
osition and movement, and to guide the placement of the
aterial. Proximal and distal ends of the stent (visible under
ltrasound) were used as landmarks to ensure that the
njection site with respect to stent placement was similar
mong arteries. Injection target location was adjacent to
he perivascular tissue.19 Delivery to the sites was con-
ys Primers sequences (5’–3’)
CTGTTGAGATCTCCCCTGGA
CGCTCAGAGGGCTGTCTATC
TCAAGGGTTGGGGTCAGTAG
GAAGTGGCCCTCCATAGACA
ACCTCGGACAGCCAACAATTCAGA
ATCCCGGAGGCTTAGGAAAGTGTT
AGGTTCCTTCCT GCCAAGTGGTAA
ATTGAGCGTCCATCCTTCAGG ACA
AGAAACCACCGGAAGGAACCATCT
ivation AGAGCTGCAGAAATCAGGAAGGCT
AGATGGTCAAGGTCGCAAGC
GGACTCCAGATGTTTCCAAACTCAACn
thwa
ll actrmed by continuous visualization of the injection site and
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Volume 56, Number 4 Nugent et al 1081blood flow during and postinjection by color-Doppler and
spectral-Doppler ultrasound scan.
Tissue processing. On the 90th postoperative day,
animals were euthanized with intravenous potassium chlo-
ride (40 mEq). The femoral arteries were perfused at 100
mm Hg with Ringer’s lactate solution, followed by 10%
neutral formalin to fix the arteries in situ. The arteries were
isolated and the vessel divided into five 10-mm-long seg-
ments: far proximal to the stent (1-3 mm upstream from
the stent), proximal stent, middle of the stent, distal stent,
and far distal to the stent (1-3 mm beyond the stent). The
stented segments were methacrylate embedded and non-
stented vessel segments were paraffin embedded. Slides
with 5-m sections were obtained and stained withMayer’s
hematoxylin and eosin and Verhoeff’s van Gieson elastin
stains. Leukocytes were identified after antigen retrieval at
80°C in 1 Dako Target Retrieval solution for 2.5 hours
and overnight incubation at 4°C with mouse antiporcine
CD45, allotypic variant (clone: MAC323, AB-D Serotec;
1:10 dilution). The CSA II detection system (K1497; Dako
Inc, Carpinteria, Calif) was used to detect primary anti-
body-tissue antigen binding. Porcine spleen was used as a
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Fig 1. Characterization of porcine aortic endothelial ce
followed a growth pattern similar to cells grown on spon
endothelial cell integrity was determined by platelet endo
indicate positive PECAM staining; blue indicates nuclei.
tory and thrombotic gene expression on human aortic
ICAM-1, Intercellular adhesion molecule-1; IL-8, inter
molecule-1. *P 	 .05 compared with PF-4 and controlpositive control and antibody diluent solution was used as a pegative control. PAE were identified as described above
ombined with avidin-biotin peroxidase complex or Alexa
luor detection methods. All sections were counterstained
ith Mayer’s hematoxylin solution (Sigma Chemical Co,
t. Louis, Mo). Slides were read and interpreted by a
oard-certified veterinary pathologist blinded as to treat-
ent groups. Histomorphologic findings were graded on a
cale from 0 through 3, depending upon severity (0 
bsent; 1  present in tissue, but minimal feature; 2 
resent in tissue, notable feature; 3  present in tissue,
verwhelming feature).21
Histomorphometric analysis was performed on all seg-
ents. The intimal thickness and area (I), lumen (L), media
M), and stent (S) areas were measured using a computer-
zed digital planimetry system comprised of an Olympus
P-70 digital, BX-41microscope and MicroSuite Biologi-
al (version 2.5) software. Measurements were made by a
linded observer of the proximal, middle, and distal seg-
ents for each vessel and averaged so that each vessel
esulted in one data point. Comparisons were also made
mong groups for each of the proximal, middle, and distal
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B
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AE) on gelatin particles. A, PAE cultured on particles
r standard tissue culture plastic. B, The preservation of
l cell adhesion molecule (PECAM) staining. Green cells
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helial cells (HAE) by PAE/matrix-conditioned media.
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standard error (SE). Statistical analysis comparing stented
arteries of the different treatment groups used a one-way
analysis of variance and a Tukey-Kramer multiple comparison
test with JMP version 7.0.1 software (SAS Institute, Cary,
NC). Differences were not considered significant unless the
probability of the calculated statistic was less than 0.05.
RESULTS
Biochemical and in vitro functional activity of
PAE/Gelfoam. PAE/matrix were assayed for cell num-
ber, viability, TGF-1, HS, NO, and TIMP-2 production.
PAE cultured on gelatin particles followed a growth pattern
similar to that observed for cells cultured on gelatin
sponges (Fig 1).16 The number of PAE recovered from the
matrix increased exponentially from 1.0 104 cells/mg on
day 0 to 6.8 104 cells/mg when they reached confluence
Fig 2. Images depict ultrasound-guided percutaneous
adjacent to perivascular tissue of femoral arteries (A) at t
site adjacent to the femoral artery was confirmed after fem
is encapsulated with injected methyl blue-stained gelatin
stained with Mayer’s hematoxylin solution confirms de
Sections of unstented femoral arteries stained with C
percutaneous injection adjacent to the perivascular tissue(day 12–15). The viability of the recovered cells was ap- 6roximately 90%. Thereafter, the cell number was fairly
onstant up to 8 days postconfluent (average of 6.1  104
ells/mg on culture day 22). Significant levels of HS
0.632  0.09 g/mL/d), TIMP-2 (23.4 1.3 ng/mL/
), NO (1.1  1.1 mol/L/day), and TGF-1 (312 
2.5 pg/mL/d) were detected in conditioned media col-
ected from postconfluent in vitro cohorts. Moreover, PAE
ultured on gelatin particles stained positive for the endo-
helial marker PECAM (Fig 1).
The inhibitory potential of PAE/matrix was further
nvestigated in growth, thrombotic, and inflammatory as-
ays. Conditioned medium inhibited growth factor stimu-
ation of cultured SMC proliferation by 36.3  1.6% (P 	
05) and suppressed the PF-4 induction of various pro-
hrombotic and proinflammatory gene expression in HAE.
AE/matrix-conditioned media significantly suppressed
he PF-4 induction of vascular cell adhesion molecule-1 by
ery of porcine aortic endothelial cells (PAE)/matrix
e of injection and (B) postinjection. C andD, Delivery
cutdown. Stent struts are visible within the artery, which
icles. E, Histologic section of unstented femoral artery
of particles adjacent to perivascular tissue. F and G,
identifies retention of PAE within the particles afterdeliv
he tim
oral
part
livery
D319.7  2.7% (P 	 .05), intercellular adhesion molecule-1
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Volume 56, Number 4 Nugent et al 1083by 40.6  12.9% (P 	 .05), tissue factor (TF) by 45.1 
6.2% (P	 .05), E-selection by 82.3 2.9% (P	 .05), and
interleukin-8 by 71.6  4.9% (P 	 .05; Fig 1).
In vivo efficacy of perivascular endothelial cells.
The pigs used in this study were randomly selected to
receive one of the following treatments by ultrasound-
guided percutaneous injection of gelatin particles into the
perivascular tissue of stented femoral arteries: PAE/matrix,
control matrix, or nothing (sham). All injections occurred
without incident (Fig 2). Acute dissection to the femoral
arteries in seven pigs confirmed location of the material and
PAE directly adjacent to the adventitia of the artery and
that a single injection of 70mg/3mL covered the length of
the stented segment (Fig 2). The remaining animals were
euthanized at 90 days. All incisions healed well, and all
animals gained weight throughout the postoperative pe-
riod. Mean hematologic and clinical chemistry values from
all groups were similar and within expected ranges. All of
the femoral arteries were patent at the 90-day time point.
Fig 3. Representative day-90 angiograms (A) and ph
sections (B). Comparison of the angiograms shows an in
and middle panels, black arrows) compared with arterie
(right panel). Histologic sections show significantly great
panel) arteries compared with arteries treated with perivaAngiographic analysis performed at 90 days postinjury re- sealed less stenosis and significantly greater MLD in the
tented segments of arteries treated with PAE/matrix (Fig
; Table II; P 	 .05). There was no difference in MLD of
ham arteries compared with arteries that received control
articles. Morphometic analysis revealed similar results (Fig
; Table III). Treatment with PAE/matrix reduced the
ntimal area from 6.20  0.50 mm2 and 4.4  0.50 mm2
or sham and matrix controls, respectively, to 3.3  0.40
m2 (P	 .05). PAE/matrix also significantly increased the
umen area from 16.1 0.90mm2 and 17.1 1.0mm2 for
ham and matrix controls, respectively, to 20.4  0.70
m2 (P	 .05) and decreased the % occlusion compared to
ham and matrix controls by 50% and 33%, respectively
P 	 .05). The average intimal area of arteries treated with
ontrol matrix was less than the sham controls (P 	 .05;
able III). However, when individual planes (proximal,
id, distal; Fig 4) were analyzed, only the PAE/matrix
roup had statistically significant less intimal area than the
icrographs of Verhoeff’s elastin-stained arterial cross-
in stenosis in the stented region of control arteries (left
ted with porcine aortic endothelial cells (PAE)/matrix
imal area in control sham (left panel) and matrix (middle
r PAE/matrix. I, Intima; L, lumen; M, media.otom
crease
s trea
er intham control group. There was no difference in stent
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October 20121084 Nugent et aldiameter observed among groups at 90 days. There were no
adverse edge effects observed in the far-proximal or far-
distal sections of any of the animals.
Histopathological analysis (Table IV) revealed no
adverse effects from perivascular injection of gelatin
particles on the perivascular tissue or tissue healing re-
sponse within the adjacent stented femoral arteries. In-
flammation at the delivery site, intimal fibrin, adventitial
fibrosis, and SMC necrosis were all minimal and compa-
rable between groups. Injury score and adventitial vas-
cularization were also assessed with no significant differ-
ences among groups. Endothelialization was generally
complete and comparable among treatment groups (Fig
5). Neointimal hypocellularity, which generally increases
in areas of mural injury with increased neointimal pro-
duction, was significantly greater in the two control
groups compared with the PAE/matrix group (Fig 5).
Fewer leukocytes (identified by CD45 staining; Fig 5)
Table II. Quantitative angiography of porcine-stented fem
Treatment Artery (mm)a B/A ratiob Acute g
Sham 3.65  0.08 1.46  0.09 0.91
Matrix 4.23  0.27 1.21  0.07 0.61
PAE/matrix 4.27  0.16 1.21  0.04 0.99
PAE, Porcine aortic endothelial cells.
aArtery, preinjury.
bB/A, Balloon/artery.
cAcute gain (deploy – artery).
dMLD, Minimum lumen diameter measured on day 90.
eLate loss (deploy – MLD).
f% Stenosis  (ref vessel – MLD)/(ref vessel)  100.
gP 	 .05 compared with control arteries.
Table III. Histopathological characteristics of stented
porcine femoral arteries
Characteristics Sham Matrix PAE/matrix
Number of
arteries, n 6 5a 6
Intima area
(mm2) 6.2  0.5 4.4  0.5b 3.3  0.4b
Neointimal
thickness
(mm) 0.40  0.03 0.29  0.04 0.20  0.02b
Lumen area
(mm2) 16.1  0.9 17.1  1.0 20.43  0.70b
Lumen/artery
ratio 0.65  0.02 0.72  0.03 0.77  0.02b
Stent diameter
(mm)c 5.5  0.13 5.4  0.07 5.6  0.04
% Occlusiond 28  2.1 21  2.8 14  1.8b
PAE, Porcine aortic endothelial cells.
aRight femoral artery of one control matrix animal removed from data
analysis due to excessive procedural injury and subsequent intimal formation
(complete occlusion).
bP 	 .05 compared with sham.
cStent diameter (Sd)  2  (Sa/).
d% Occlusion  (I/I  L)  100.were present in the intima in the PAE/matrix group tompared with the matrix (average difference of one
everity point) and sham (average difference of two
everity points) control groups. No positive staining for
D45 was observed in the media of any animals. Mini-
al CD45 staining was present in the adventitia with no
ifferences observed between groups.
ISCUSSION
Despite the improvements in endovascular techniques in
he last 20 years, restenosis is still a significant limitation of
ost arterial interventions performed in the peripheral circu-
ation.8 In particular, interventional treatments in the SFA
ave long suffered from excessively high restenosis rates re-
ardless of treatment with balloon angioplasty and stent-
ng.5,22 Several studies have also reported stent fractures when
sed in the SFA that have been associated with angiographic

50%) stenosis. Currently, no large, randomized trials have
hown significant clinical benefit with the use of drug-eluting
tents6 or other agents such as glycoprotein IIb/IIIa platelet
eceptor-blocking agents23 for restenosis associated with pe-
ipheral arterial interventions.
The endothelial technology presented here represents a
ovel approach to addressing the complications associated
ith peripheral interventions. The use of ECs to modify
ntravascular injury has been under active investigation for
ome time, primarily in the form ofmethods to endothelialize
tents and/or the damaged native vessel.24,25 However,
he ability of ECs to regulate neointimal formationmay not be
imited to a luminal location, and studies have suggested that the
dventitia and vasa vasorum influence the vessel response to
njury.11,12 Perivascular placement also presents a desirable loca-
ion for logistical reasons – the cells and their secreted factors are
ot diluted or rapidly cleared by convective flow, nor do they
mpede flow. Indeed, implantation of perivascular, allogeneic
issue-engineered ECs has been shown to regulate the response
o vascular injury and decrease stenoses13-16,26 and has been
nvestigated in the clinical setting of arteriovenous access for
emodialysis.27 However, all of these studies utilized a
orous, three-dimensional sponge as the support matrix
or implantation of quiescent and therapeutic ECs. The
pplication of this technology was therefore limited to
hose that require an open surgical procedure. An aim of
arteries
mm)c MLD (mm)d Late loss (mm)e % Stenosisf
11 4.03  0.16 0.72  0.49 15.0  4.0
55 4.01  0.20 0.85  0.40 17.0  4.0
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planes. PAE, Porcine aortic endothelial cells.
calculated per plane (0  IEL intact; 1  IEL disrupted; 2  tunica media
disrupted; 3  tunica adventitia disrupted).
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Volume 56, Number 4 Nugent et al 1085ould be adapted to an injectable formulation and deliv-
red utilizing a minimally invasive procedure, and if such
delivery would produce efficacy in vivo. The necessity
f culturing ECs on matrices prior to implantation rather
han direct injection of cell suspensions has been dem-
nstrated previously.28-31 ECs are anchorage-dependant
nd require attachment to a substrate for optimal viabil-
ty and function.16,28,32 Indeed, recent literature has
ighlighted the importance of developing transplantable
caffolds that optimize cell attachment, viability, and
unction to the widespread use and success of cell trans-
lantation to treat or prevent organ and tissue failure.17
t has also been shown that matrix-adhered ECs have
ignificantly reduced expression of constitutive and cytokine-
pregulated costimulatory and adhesionmolecules compared
ith freeECs, and in particular, amarked abrogation ofMHC
I-regulated immune reactivity, resulting in muted host im-
une reaction to both allogeneic or xenogeneic matrix-ad-
eredECs.28We therefore developed amatrix-embeddedEC
ormulation that was amenable tominimally invasive injection
hile maintaining a regulatory phenotype that maximally
ontrolled inflammation, intimal thickening, and mural re-
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Characteristic Sham Matrix PAE/matrix
Intimal fibrin 0.06  0.04 0.0  0.0 0.0  0.0
Endothelializationa 4.0  0.0 4.0  0.0 4.0  0.0
Adventitial fibrosis 1.0  0.32 0.33  0.27 0.72  0.16
Neointimal
hypocellularityb 1.33  0.12 1.1  0.22 0.44  0.14c
Medial smooth
muscle cell
necrosis 0.28  0.13 0.0  0.0 0.06  0.06
Adventitial
vascularization 0.0  0.0 0.0  0.0 0.0  0.0
Inflammationd 0.61  0.04 0.53  0.09 0.60  0.16
Injury scoree 0.04  0.04 0.0  0.0 0.1  0.04
PAE, Porcine aortic endothelial cells.
aEndothelialization was scored on a scale from 0 to 4 (0 absent; 1	 25%;
2  25-75%; 3
 75%; 4  100%) and depended upon the extent of the
circumference of the artery lumen showing coverage with endothelial cells.
bCharacterized by areas of neointima with increased interstitial matrix
within/around smooth muscle cells.
cP 	 .05 compared with control arteries.
dSum of strut inflammation scores/No. of stent struts.
eThe injury score depended on the part of the arterial wall perturbed by the
stent. Injury was scored from 0 to 3 on a per-strut basis and the average wasodeling.
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ilar levels of HS, TGF-1, FGF-2, NO, and TIMP-2 to that
from cells grown on the sponges, suggesting that both
types of matrices supported the quiescent and therapeutic
endothelial phenotype.33 This was confirmed in vivo by the
ability of PAE/matrix, injected percutaneously under ultra-
sound guidance, to inhibit intimal formation and stenosis
in a porcine femoral stent model. A stent model was used to
assess the ability of the PAE/matrix to control the response
to a chronic vascular injury and to precisely locate the area
of injury at a late time point. Because the PAE/matrix, as
well as the gelatin matrix alone, degrades in vivo within 6 to
8 weeks, a 90-day time point was selected for this study to
assess the durability of therapeutic effects.14,15 Stented
arteries in the PAE/matrix group had significantly greater
MLD by angiography and significantly greater lumen area
and less intimal formation compared with sham controls
by histology at 90 days. It is interesting to note that upon
initial evaluation of histologic samples, the injection of
Fig 5. Representative photomicrographs of hematoxyl
endothelialization (arrows), (B) reduced hypocellularity i
circle) compared with (C) control matrix group (dashed
struts (arrow) in PAE/matrix group. E, Representative
depict no positive staining in the intima of PAE/matrix ar
matrix (middle panel) and sham (bottom panel) group
demonstrates fewer CD45-positive leukocytes (severity
animals compared with control matrix (severity score matrix alone, while not as great a difference as injection df matrix containing PAE, appeared to have some bene-
cial effects on intimal area compared with the sham
ontrol. However, upon further detailed analysis of his-
ologic planes (Fig 4), there was no significant therapeu-
ic effect of the matrix group. This was also the case for
he angiographic analysis; control sham and matrix
roups had almost identical MLD, while the PAE/
atrix groups have a significantly larger MLD. Further-
ore, it also appears that only the PAE/matrix group
ruly inhibited leukocyte infiltration into the intima. It is
herefore more likely that the therapeutic benefits are
ue to the presence of the matrix-embedded cells and
ot the matrix alone.
Adverse events that have been associated with drug-
luting stents include inflammation, fibrin deposition, me-
ial necrosis, intra-arterial hemorrhage, and incomplete
ealing or endothelialization at the stent struts.34 All of
hese phenomena were evaluated in the present study. All
tented vessels were completely endothelialized by the 90-
d eosin-stained arterial cross-sections depict (A) stent
cine aortic endothelial cells (PAE)/matrix group (dashed
ckets), (D) minimal inflammation associated with stent
tomicrographs of CD45-stained arterial cross-sections
(top panel) andmoderate positive staining in the control
rrows point to positive CD45 staining. F, Bar graph
 0  0) present in the intima of day 90 PAE/matrix
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of perivascular PAE/matrix. Indeed, analysis of CD45-
stained tissue sections from PAE/matrix animals revealed
no leukocytes present in the intima of the arterial segments,
compared with a moderate degree of CD45 cells in the
control groups. This observation suggests that perivascular
ECs, or factors released by the cells, may provide control
over intimal formation by influencing the inflammatory
phase of the vascular response to stent-induced in-
jury.9,10,35 This is similar to the proposed mechanism of
mesenchymal stem cell (MSC) transplantation, where
MSCs have been shown to modulate T-cell-mediated im-
munologic responses and inhibit dendritic cell maturation
through paracrine interactions with MSC-soluble fac-
tors.29,36 The in vivo data are further supported by the in
vitro results. Conditioned media collected from PAE
grown on gelatin particles suppressed PF-4 induction of
prothrombotic and proinflammatory genes in cultured
HAE and inhibited growth factor-stimulated SMC prolif-
eration.
In addition, placement of the PAE/matrix in the ad-
ventitia and not associated with a stent has the advantage of
allowing for application in clinical settings where stent
placement may not be feasible, such as arteries located
below the knee. A limitation of the present study was that
the animals were healthy, and therefore the impact of
angioplasty and stenting of an existing lesion was not
assessed; however, the results suggest that percutaneous
delivery of tissue-engineered EC to the adventitia promotes
vascular repair after stent-induced injury. Injections of
tissue-engineered ECs coincident with balloon angioplasty
or stenting of peripheral arteries may improve the long-
term success rates of these procedures. A clinical study
assessing the safety and feasibility of ultrasound-guided
percutaneous injections of tissue-engineered endothelium
(derived from allogeneic human aortic endothelial cells) in
patients undergoing stent placement in the SFA is currently
ongoing.
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